December 16, 2022 - Non-regulatory SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA
November 1, 2022 - Non-regulatory SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA
September 27, 2022 - Non-regulatory SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA
August 16, 2022 - Non-regulatory Resomelagon proposed international nonproprietary name (INN) for AP1189
July 21, 2022 - Non-regulatory SynAct Pharma improves the design of the ongoing Phase 2a study in iMN
April 1, 2022 - Non-regulatory SynAct publishes prospectus in connection with a fully guaranteed rights issue
